Pertuzumab [clinicaltrials_resource:ad4cae995e70a68b5ba123279b524637]
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors [clinicaltrials:NCT00027027]Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer [clinicaltrials:NCT00058539]A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer [clinicaltrials:NCT00058552]clinicaltrials:NCT00063154clinicaltrials:NCT00096941clinicaltrials:NCT00096993Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab [clinicaltrials:NCT00301899]A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. [clinicaltrials:NCT00545688]clinicaltrials:NCT00551421clinicaltrials:NCT00567190clinicaltrials:NCT00855894clinicaltrials:NCT00875979A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer [clinicaltrials:NCT00934856]clinicaltrials:NCT00943670A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors [clinicaltrials:NCT00947167]A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer [clinicaltrials:NCT00951665]A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer [clinicaltrials:NCT00976989]A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) [clinicaltrials:NCT01026142]clinicaltrials:NCT01042379Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer [clinicaltrials:NCT01048099]clinicaltrials:NCT01108458A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) [clinicaltrials:NCT01120184]clinicaltrials:NCT01121939clinicaltrials:NCT01276041A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer [clinicaltrials:NCT01358877]A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer [clinicaltrials:NCT01461057]A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer [clinicaltrials:NCT01491737]clinicaltrials:NCT01501487A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer [clinicaltrials:NCT01565083]A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) [clinicaltrials:NCT01572038]Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 [clinicaltrials:NCT01597414]clinicaltrials:NCT01669239A Study of Perjeta (Pertuzumab) in Combination With Herceptin in Patients With Metastatic Breast Cancer. [clinicaltrials:NCT01674062]A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression [clinicaltrials:NCT01684878]Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer [clinicaltrials:NCT01730833]A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer [clinicaltrials:NCT01774786]Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa [clinicaltrials:NCT01796197]Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) [clinicaltrials:NCT01805908]A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol [clinicaltrials:NCT01817452]clinicaltrials:NCT01835236
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Pertuzumab [clinicaltrials_resource:ad4cae995e70a68b5ba123279b524637]
Bio2RDF identifier
ad4cae995e70a68b5ba123279b524637
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ad4cae995e70a68b5ba123279b524637
identifier
clinicaltrials_resource:ad4cae995e70a68b5ba123279b524637
title
Pertuzumab
@en
type
label
Pertuzumab [clinicaltrials_resource:ad4cae995e70a68b5ba123279b524637]
@en